Table II.
Clinical and epidemiologic characteristics of patients with severe asthma diagnosed with COVID-19
| Characteristic | Drug |
P Value | |||
|---|---|---|---|---|---|
| Omalizumab | Mepolizumab | Reslizumab | Benralizumab | ||
| N (%) | 14 (5.32) | 11 (7.14) | 3 (11.54) | 7 (7.14) | |
| Sex: female, N (%) | 10 (71.43) | 5 (45.50) | 1 (33.00) | 5 (71.40) | NS |
| BMI, mean ± SD | 26.71 ± 6.30 | 26.04 ± 4.26 | 25.73 ± 2.40 | 27.00 ± 4.70 | NS |
| Age (y), mean ± SD | 46.36 ± 12.21 | 56.45 ± 5.30 | 49 ± 12.12 | 60.29 ± 11.30 | NS |
| FEV1%, mean ± SD | 84.52 ± 22.65 | 83.35 ± 21.02 | 76.00 ± 2.83 | 85.97 ± 7.38 | NS |
| Arterial hypertension, N (%) | 3 (21.43) | 4 (36.40) | 0 (0.0) | 2 (28.60) | NS |
| Diabetes, N (%) | 0 (0.0) | 1 (9.09) | 0 (0.0) | 0 (0.0) | NS |
| CRSwNP, N (%) | 8 (57.14) | 8 (72,73) | 3 (100) | 3 (42.86) | NS |
| Hospital admission | 1 (11.1) | 3 (33.33) | 2 (66) | 2 (28.60) | NS |
| ICU admission, N (%) | 1 (7.14) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS |
| Exitus, N (%) | 0 (0.0) | 1 (9.09) | 0 (0.0) | 0 (0.0) | NS |
| OR | 0.70 | 1.18 | 1.99 | 1.15 | |
| P value | .38 | .67 | .23 | .82 | |
| 95% CI | 0.35-1.38 | 0.55-2.41 | 0.60-6.36 | 0.46-2.74 | |
| β error | 0.83 | 0.92 | 0.73 | 0.93 | |
BMI, Body mass index; CRSwNP, chronic rhinosinusitis with nasal polyps; ICU, intensive care unit; OR, odds ratio; NS, not statistically significant.
The possibility that COVID-19 occurs in one treatment group vs the risk that occurs in another treatment group has been expressed as OR. The OR for each group compares that group to all other groups combined.